A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension

Phase 3 Enrolling by invitation 1000 enrolled United Therapeutics

NaSingle-groupOpen-labelTreatment

Summary

Study ROR-PH-303, ADVANCE EXTENSION, is an open-label extension (OLE) study for participants with WHO Group 1 PAH who have participated in another Phase 2 or Phase 3 study of ralinepag.

Timeline

Start: 2019-09-23
Primary completion: 2026-12
Completion: 2026-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ralinepag	Small molecule	50 ug	Oral
Subject	Ralinepag	Small molecule	250 ug	Oral
Subject	Ralinepag	Small molecule	400 ug	Oral

A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension

Summary

Timeline

Drugs

Indications